



CAPA e Newsletter



CHINESE AMERICAN PATHOLOGISTS ASSOCIATION

~ 全美华人病理学会 ~

VOLUME 1 ISSUE 2 2015

In this issue:

Announcements of CAPA Major Events for 2015-2016	P1
CAPA letter to SCAPE	P1-P2
Highlights of the CAPA Annual Meeting in Boston	P1-P3
ACAP Summary with Photos	P3
Introducing CAPA Pathologists/Scientists	P4
Anatomic Pathology Billing Highlights for 2015	P4-P5
Recent Achievements from CAPA Members	P5-P6
Advertisements for CAPA Sponsors	P6

Editing Team:

Huan-You Wang
 Jun Zhang
 Fan Chen
 Jie Song
 Zenggang Pan
 Kar-Ming Fung
 Longwen Chen
 Yajue Huang
 Huimiao Jiang

Design:

Fan Chen



Announcements of CAPA Major Events for 2015-2016

August 22-24, 2015
 Sheraton LaGuardia East Hotel,
 Flushing, New York

The First Chinese American Pathologists Association (CAPA) Diagnostic Pathology Course - Best Practices in Diagnostic Immunohistochemistry for Both Surgical Pathology and Cytopathology

For the meeting details and registration please go to <http://www.capaht.org>

October 16-18, 2015
 Chinese Academy of Medical Sciences,
 Cancer Institute, Beijing, China

第一届中美肿瘤诊断病理高峰论坛暨《诊断性免疫组化应用-回顾与更新》专题讨论。

This is the first time that CAPA and Cancer Institute of Chinese Academy of Medical Sciences jointly organize this conference on tumor diagnostic pathology. Eight pathologists will represent CAPA to present at this meeting. They are Hui Chen (MD Anderson Cancer

Center), Zongming Chen (Geisinger Medical Center), Charles Guo (MD Anderson Cancer Center), Fan Lin (Geisinger Medical Center), Haiyan Liu (Geisinger Medical Center), Ping Tang (University of Rochester), Hong Wu (Fox Chase Cancer Center), Ximing Yang (University of Northwestern)

November 6-8, 2015
 Kunming, Yunnan

The 2015 Annual Meeting of Chinese Society of Pathology

Over 10 speakers (will be announced soon) will represent CAPA to present at this meeting in different formats including Pathology Training Course, Case-Based Presentation, and Oral Presentation.

March 12, 2016
 Seattle, WA

The 14th Annual Meeting of Chinese American Pathologists Association

Details to be followed

CAPA Letter to SCAPE

The following letter has been sent to the SCAPE leadership team on August 1, 2015.

Dear Dr. Qian and SCAPE Leadership team:

I send this letter on behalf of my organization, Chinese American Pathologists Association ("CAPA"), regarding your organization's unauthorized use of CAPA's logo. Attached below is the email I previously sent on June 30, 2015 (not attached here), requesting that SCAPE remove CAPA's logo from SCAPE's website. I was pleased to find that SCAPE honored my request by removing CAPA's logo. But it is unclear to CAPA how SCAPE's unauthorized use of CAPA's logo may have influenced, or perhaps misled, visitors to your website. As you are aware, there is no direct relationship or agreement between our organizations.

(Cont'd on Page 2)

Highlights of the CAPA Annual Meeting in Boston



Dr. Jim Zhai,
 CAPA President
 2014-2015, presenting CAPA
 Annual Report

Dr. Gene Herbeck, CAP President, addressing CAPA members and encouraging more interactions between CAP and CAPA

(Cont'd on Page 2)



CAPA Letter to SCAPE

(Cont'd from Page 1)

Thus, any impression that SCAPE is related to or endorsed by CAPA is untrue. CAPA will not accept liability for any injuries allegedly arising from or in connection with this incident.

As you may be aware, CAPA's logo is a trademark of CAPA, and the content of CAPA website may be copyright protected. CAPA reserves the ability to enforce its intellectual property rights.

As you may also be aware, CAPA is a not-for-profit organization. The primary mission of CAPA is to improve educational opportunities and professional skills of practicing pathologists of Chinese ethnicity by promoting communication, friendship and cultural exchange, and by advancing the science and practice of pathology and laboratory medicine. CAPA is not currently involved in any commercial activities and has no plan to do so in the near future.

CAPA, however, is open to collaborate with other organizations or individuals where doing so furthers CAPA's mission. Therefore, if it is SCAPE's intention to collaborate with CAPA, I invite you to establish a dialogue with me and my leadership team so that we may constructively explore any such possibilities.

Sincerely,

Fan Lin
 President of CAPA, 2015-2016
Flin1@geisinger.edu
 CAPA Executive Committee

Highlights of the CACA Annual Meeting in Boston

(Cont'd from Page 1)



Dr. Richard Friedburg, CAP President-elect, calling for more CAPA members to be involved with CAP various committees




ACD Distinguished Pathologist Awards, presented by Yuling Lou (left), ACD Founder and CEO, sponsor of this award.

Dr. Ximing Yang (center), receiving the inaugural award "CAPA

Dr. Qinghu Ren (center) receiving CAPA Gopath Best Abstract Award. Dr. Chengquan Zhao (left first), Chair of this award committee. Dr. James Lu, the founder and CEO of Gopath and sponsor of this award.



Dr. Xiuwu Bian (center) receiving the inaugural award "CAPA ASCP Distinguished Pathologist Award", presented by Dr. Blair Holladay (right), Executive VP of ASCP



Dr. Fang Fan (left), CAPA treasurer 2013-2015, receiving the "CAPA Zu-Hua Gao President Best Service Award".



Group picture with CAP leaders



ACD Distinguished Pathologist Awards, presented by Yuling Lou (left), ACD Founder and CEO, sponsor of this award.

Dr. Qin-Lee Wu (center) receiving the inaugural award "CAPA



CAPA Motic Best Abstract Awards recipients:

Dr. Fangfang Liu (left second), and Dr. Dongmei Lin (right second) from Beijing University Cancer Center. Dr. Huamin Wang (left first), Chair of this award committee and Dr. Chen Zhou, member of CAPA Executive Committee



Dr. Fan Lin, CAPA President 2015-2016, outlining the exciting looking forward.

(Cont'd on Page 3)

The 13th annual pathology symposium of ACAP

The 13th annual pathology symposium of Association of Chinese American Physicians (ACAP) was held on Sunday June 7th, 2015 in Flushing, New York. More than 70 pathologists/pathology trainees of Chinese ethnicity from New York, New Jersey, Connecticut and Pennsylvania attended this well-known scientific and social activity. Over the years, hospitals in New York City trained a significant number of pathologists of Chinese ethnicity, many of them are now noted figures in their sub-specialties. This year's symposium focused on genitourinary (GU) pathology, with in-depth discussion on advances in molecular pathology of the urinary tract (Jiaoti Huang, UCLA), neoplastic diseases of the testis (Charles Guo, MD Anderson Cancer Center), urothelial carcinoma (Hikmat A.



Al-Ahmadie, Memorial Sloan Kettering Cancer Center), new and emerging entities of renal cell carcinoma (Yingbei Chen, Memorial Sloan Kettering Cancer Center), GU pathology from a surgeon's point of view (William C. Huang, NYU), and benign mimickers of prostate cancer (Fang-Ming Deng, NYU). This year's symposium also marks the first collaboration between ACAP pathology committee and Chinese American Pathologists Association (CAPA) in meeting organization. Both Dr. Jiaoti Huang and Dr. Charles Guo were recom-



mended by CAPA. Coincidentally, both speakers are also alumni of NYU. The organizing committee of this symposium includes doctors Fang-Ming Deng, Jim Zhai, Dong-Sheng Xu, Ruliang Xu, Ming Zhou, and He Wang. Dr. Fang-Ming Deng hosted the symposium.

Highlights of the CACA Annual Meeting in Boston

(Cont'd from Page 2)



Dr. Fan Li ((left first), CAPA

President 2015-2016, Dr. Ping Tang (left second), CAPA President-elect 2017-2018, Dr. Huamin Wang, (right second) CAPA President-elect 2016-2017

Right: Dr. Shuan Li, former CAPA President, checking in.



Dr. Ping Tang (left first), Dr. Mujun Yu (left second), Dr. Lizhen Gui (center), Dr. Lirong Zhao (right second), and Dr. Songjing Zhao (right first).



Drs. Ruoqing Huang, Beverly wang, Shuan Li, Dongfeng Tan, Zhongren Zhou (from left to right)



Drs. Xiuli Liu, Robert Pu,



Drs. Baoying Wen (left first), Wei Wng (left second), Chengquan Zhao (left third), Marilyn Bui (right third) with fellow pathologists practicing in China Drs. Gengyen Zhou (center), Tingguo Zhang (right second), and Bo Gao (right first)

Below: Dr. Lanjing Zhang (right first) with fellow pathologists practicing in China, Dr.




Jingping Yun (left first), Dr. Dongmei Lin (left second), and Guifang yang (right second)

Right: CAPA members having Dim Dum gathering




INTRODUCING CAPA PATHOLOGISTS/SCIENTISTS



Dr. Xiaoping Sun's research interest is in the molecular and cellular mechanisms underlying the early development of normal B lymphocytes and its malignant counterpart, the origin and progression of B-cell ALL. One of the studies in his lab was to elucidate the role of the Sox4 gene in the development from hematopoietic stem cells to mature B lymphocytes. By using sophisticated lab technologies, such as in vivo and in vitro knockout, primary cell culture, gene expression microarray, and ChIP-Seq, Dr. Sun's team uncovered a complex gene network controlled by Sox4 in B cell progenitors. In in the same issue of the journal *Blood* (June 2014) where the study of Dr. Sun's group was published (pubmed ID: 24786772), Dr. Barbara Kee at the University of Chicago wrote in her expert commentary: "this study provides a foundation for further understanding of" Another paper from Dr. Sun's lab recently published also in *Blood* (May 2015; pubmed ID: 25712988) reported a novel mechanism of drug resistance in B-cell ALL, i.e., drug-induced mesenchymal stem cell-mediated drug resistance. In the same issue of the journal, as an expert in the same field Dr. Markus Muschen at UCSF commented on the study: "novel and unexpected" and "timely and important". (Xiaoping Sun, MD, PhD, Associate Professor, Department of Laboratory Medicine, MD Anderson Cancer Center. MD, 1984, Zhejiang Medical University, Hangzhou; MS, 1990, Shanghai Institute of Cell Biology, Chinese Academy of Sciences; PhD, 1994, Catholic University of Nijmegen, The Netherlands, and Shanghai Institute of Cell Biology, Chinese Academy of Sciences; postdoctoral fellowship, 1994-1998, The Salk Institute for Biological Studies, La Jolla, CA; residency in AP and CP, 1998-2002, Northwestern University Medical School, Chicago, IL; hematopathology fellowship, 2002-2003, MD Anderson Cancer Center; at present work location since 2003. Research grants from NIH, ACS, MD Anderson, Ladies Leukemia League.)

Xiaowei Xu, MD, PhD, is Associate Professor of Pathology and Dermatology at the University of Pennsylvania, Philadelphia, USA. Dr. Xu received his medical degree from Fudan University, Shanghai, China in 1992 and graduate degree from Wake Forest University, Winston-Salem, North Carolina 1996. He received his Anatomic and Clinical pathology residency training at the University of Pennsylvania and Dermatopathology fellowship training at Harvard. He did his post-doctoral research training at the laboratories of Drs. William Sonntag at the Wake Forest University and George Cotsarelis at the University of Pennsylvania. He is board certified in Anatomic Pathology, Clinical Pathology and Dermatopathology. He joined the faculty at the University of Pennsylvania and served as an attending physician specialized in dermatopathology at the Hospital of University of Pennsylvania in 2002. He is the Associate Editor of *Lever's Histopathology of Skin*, one of the most widely used textbooks in Dermatopathology. He is on the editorial board of 6 medical journals and reviewers for many journals. He is a reviewer for many NIH study sections and foundations. His laboratory is funded through RO1, R21, PO1, Specialized Programs of Research Excellence (SPORes) and foundation grants. His lab focuses on hair follicle, melanocyte and melanoma biology. He has been involved in multiple clinical trials, including two landmark trials discovering the use of vemurafenib and imatinib in melanoma patients. He has published over 130 peer reviewed manuscripts in journals such as *Nature*, *Nature Communications*, *Cancer Cell*, *Molecular Cell*, *Developmental Cell*, *Journal of Clinical Oncology*, *Journal of Clinical Investigation* and *PNAS*. News about his research appeared on Yahoo front page, CBS and NBC news as well as many other news outlets. His work has been cited by his peer researchers for over 7000 times and his h-index is 42. He has multiple patents in the area of hair follicle, melanocyte and melanoma research. He has trained hundreds of pathology residents and fellows and many of his trainees are practicing dermatopathologists in the states.



Anatomic Pathology Billing Highlights for 2015

Every year, Centers for Medicare and Medicaid Services (CMS) publishes a Physician Fee Schedule (PFS) that contains the payment rates for all medical services, including pathology services, provided by doctors. Even though PFS only applies to Medicare payments, it essentially determines doctor's earning because most insurance companies link their reimbursement rates to Medicare's. The payment rates for Anatomic Pathology (AP) services experienced major cuts in 2013-2014. Fortunately, the 2015 rates will remain relatively stable. CAP predicts no significant changes in the overall pathology payments. However, the impact on individual pathologist or group could still be significant, depending on the volume and the type of services the doctor bills. Many CPT codes, including 88305 (most biopsies), 88307, 88309, special stains 88312/88313, will have the same rates with minimal changes. The professional component (PC) payments are: 88304 - \$11, 88305 - \$38, 88307 - \$85, 88309 - \$151, 88312 - \$27, 88313 - \$12, approximately. This article will focus on PC payments only. Significant cuts are seen in immunohistochemistry (IHC), in-situ hybridization (ISH/FISH), and prostate biopsies. These three areas were regarded by CMS as potentially overvalued.

For IHC, 88342 (first marker) and 88341 (additional marker) replaced G0461 and G0462, two temporary codes used in 2014. A new code 88344 is added for multiplex stains such as PIN-4. All IHC codes are now paid "per specimen". For example, if S100 and Melan-A stains are performed on three blocks of a sentinel lymph node, only one unit of 88342 and 88341 can be billed. The payments actually increased slightly from 2014 to 2015: \$30 to \$36 for 88342, \$12 to \$21 for 88341. The global payments (PC + TC) stayed the same. All payments are significantly lower than 2013 rates. (Cont'd on Page 5)


Recent Achievements from CAPA Members

Promotion:

Dear CAPA members,

I am very excited and eager to share this very wonderful news with you! Dr. Jiaoti Huang has been named the new chair of the Department of Pathology, at Duke University, School of Medicine! Yes, Duke University, one of the most prestigious medical schools in U.S. Many of us know Jiaoti and I am sure that we all are very proud of him for this incredible achievement. Jiaoti's huge success will set an example for many young Chinese pathologists and inspire others to pursue this path. Please see the link below for the whole story.

<https://medschool.duke.edu/about-us/news-and-communications/med-school-blog/huang-named-new-chair-department-pathology>



Congratulations Dr. Huang!!!

Fan Lin

CAPA President, 2015-2016

Dr. Yun Gong was promoted to tenured full professor at the University of Texas M.D. Anderson Cancer Center starting from September 1, 2015.

Dr. Huamin Wang was promoted to tenured full professor at the University of Texas M.D. Anderson Cancer Center starting from September 1, 2015.

Publications

1. **Kong M**, Drill EN, Morris L, West L, Klimstra D, Gonen M, Ghossein R, Katabi N. Prognostic factors in myoepithelial carcinoma of salivary glands: A Clinicopathologic Study of 48 Cases. *Am J Surg Pathol.* 2015 JUL;39(7):931-8. PMID: 25970687
2. **Wang HY**, McMahon C, Ali S, Ross JS, Young LE, Yekezare S, and Ball ED. Novel FNDC3B and EVI1 Fusion and Frameshift Mutation in an Acute Myeloid Leukemia with Cytomorphologic and Immunophenotypic Features Reminiscent of Acute Promyelocytic Leukemia. *British Journal of Haematology* 2015 Jul 6. doi: 10.1111/bjh.13552. PMID: 26147192
3. Tomlin J, Orosco RK, Boles S, Tipps A, Husseman J, **Wang HY**, and Wieduwilt M. Successful Treatment of Multifocal Histiocytic Sarcoma Occurring after Renal Transplantation with Cladribine, High-dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) Followed by Allogeneic Hematopoietic Stem Cell Transplantation. *Case Reports in Hematology.* doi.org/10.1155/2015/728260. PMID: 26167311
4. Ruifeng Yang, Ying Zheng, Michelle Burrows, Shujing Liu, Zhi Wei, Arben Nace, Wei Guo, Suresh Kumar, George Cotsarelis & **Xiaowei Xu**: Generation of Folliculogenic Human Epithelial Stem Cells from Induced Pluripotent Stem Cells. *Nature communications* 2014 | 5:3071 | DOI: 10.1038/ncomms4071 p1-11

Lectures and Courses:

(Cont'd on Page 6)

Dr. Fan Lin (Speaker): Pathology Grand Rounds at Department of Pathology and Lab Med, Temple University Hospital
Topics: 1) Undifferentiated carcinoma: using IHC approach; 2) IHC Quality Management Philadelphia, PA May 22, 2015

Drs. Yun Gong and Fang Fan (Speakers): Short Course/Workshop at the 62nd Annual Scientific Meeting of American Society of Cytopathology (ASC) "Traps and tips in daily FNA cytology"

Anatomic Pathology Billing Highlights for 2015

(Cont'd from Page 4)

For ISH/FISH, 88365 (first probe) dropped 26%, from \$60 to \$44. The new code 88364 (additional probe) has an even lower rate (\$27). A new code 88366 is created for multiplex stains. It gets more complicated when morphometric analysis is involved. The codes (automatic/manual) are: 88367/88368 (first probe), 88373/88369 (additional probe), and 88374/88377 (multiplex). The payment cut can be quite significant because of these new codes. For example, for a pair of kappa/lambda ISH, in 2014 one could bill 88365 x 2 (\$60 x 2 = \$120), while in 2015 one can only bill 88365 + 88364 (\$44 + \$27 = \$71). Another example, a manual quantitative multiplex FISH panel, HER2/CEP17, could be billed 88368 x 2 (\$64 x 2 = \$128) in 2014, now can only be billed one 88377 (\$65). Practices with a high volume of FISH may see a large drop in revenue. For prostate biopsies, CMS decided to use a single code G0416 for all biopsies of one prostate, regardless of the number of cores. For example, a twelve-core biopsy set (in 12 separate containers) could be billed 88305 x 12 (\$38 x 12 = \$456) in the past, now can only be billed with one unit of G0416 (\$182). The impact on GU-only pathology labs can be huge. CMS just released its proposed 2016 PFS in July, 2015. The good news is there is a predicted 8% increase in overall pathology payments. There is a nearly 30% increase for 88341-PC and 88364-PC. There are also significant increases in technical component payments for ISH/FISH, particularly payments for "additional probes" (88377, 88374, 88373, 88369, 88364). The proposed PFS won't be finalized until November. For more details, visit www.cap.org and select "Get Involved", then "Advocacy".

Recent Achievements from CAPA Members

Lectures and Courses:

(Cont'd from Page 5)

Dr. Jim Zhai (Mayo Clinic Florida) (**Organizer**): Head and Neck Pathology Long course at the 9th Asia Pacific International Academy of Pathology (APIAP) Congress at Brisbane, Australia. June 4, 2015

Speakers:

Dr. Haodong Xu [University of California at LA (UCLA)]: What is new is HPV-associated squamous cell carcinoma?

Dr. Jim Zhai: Practical approach to salivary glands tumors

Dr. Yun Gong (MD Anderson Cancer): Traps and Tips in FNA Diagnosis of Thyroid Bed.

Dr. Ming Zhou (New York University) and **Dr. Jim Zhai** (Mayo Clinic Florida) (**Course co-directors**): Short Course on Frozen Section at the 9th Asia Pacific IAP Congress, Brisbane Australia. June 4-7, 2015

Speakers:

Dr. Jim Zhai: The common pitfalls and challenges in frozen section diagnosis in head and neck

Dr. Ming Zhou: The common pitfalls and challenges in frozen section diagnosis in genitourinary system

Dr. Huamin Wang (UT M. D. Anderson Cancer Center): The common pitfalls and challenges in frozen section diagnosis in pancreaticobiliary system

Dr. Longwen Chen (Mayo Clinic Arizona): The common pitfalls and challenges in frozen section diagnosis in gynecologic system


Dr. Jing Zhang (University of Washington): The common pitfalls and challenges in frozen section diagnosis in neuropathology

From left to right: Dr. Jing Zhang, Dr. Jim Zhai, Dr. Ming Zhou, Dr. Linda Shen (Australian IAP), Dr. Huamin Wang, Dr. Longwen Chen, and Dr. Honggang Liu (Head neck pathologist in Beijing).



ADVERTISEMENTS FOR CAPA SPONSORS

Delivering high quality IHC service and providing expertise, information and education to diagnostic pathologists.




For more information, visit geisingerihc.com or call 800.695.6491.

geisingerihc.com

GEISINGER IHC

MXB
Biotechnologies


Maixin provides comprehensive range of solutions for immunohistochemistry



Biotechnologies

福州迈新生物技术开发有限公司

☎ : 400-8889-853/800-8881-156



Broadest portfolio of FDA-cleared image analysis algorithms with the VENTANA Digital Pathology Solution

■ER ■PR ■HER2 ■Ki-67 ■p53

VENTANA and the VENTANA logo are trademarks of Roche.
© 2015 Roche Diagnostics Corporation
9115 Hague Road • PO Box 50414 • Indianapolis, IN 46250

10 MINUTE
INTRAOPERATIVE
DIRECT IHC

Time In Minute	Procedure
0.5	Fixation
0.1	Wash in PBS
0	No Blocking
5	PolyHRP-Antibody
0.1	Wash in Water
1	DAB
0.1	Wash in Water
2-3	Counter Staining + Dehydration + Coverslipping
9-10	Total Time

Available Products:

- ihcDirect AE1/AE3
- ihcDirect Mart-1
- ihcDirect CK8/18
- ihcDirect Synaptophysin
- ihcDirect Herceptin

NOVODIAX

VISIT www.novodiox.com
CALL 1.888.439.2716
EMAIL novoinfo@novodiox.com